Joining the TL1A space, AbbVie has signed a global license agreement with FutureGen to focus on the development of FG-M701, a TL1A antibody for the treatment of inflammatory bowel disease (IBD). The alliance, which involves a US$150 M upfront payment and up to US$1.56 B in milestones, will provide AbbVie with an exclusive license to develop, manufacture and commercialise the preclinical candidate. The deal aligns with AbbVie’s commitment to bolstering its immunology portfolio in an attempt to offset the losses of Humira due to generic erosion.